Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients

Juan Palou; Oriol Angerri; José Segarra; Juan Caparrós; Luis Guirado; Juan Manuel Diaz; José Salvador-Bayarri; Humberto Villavicencio-Mavrich

doi:10.1097/01.TP.0000090748.32764.0F

Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients

Juan Palou, Oriol Angerri, José Segarra, Juan Caparrós, Luis Guirado, Juan Manuel Diaz, José Salvador-Bayarri, Humberto Villavicencio-Mavrich

Department of Surgery

Research output: Contribution to journal › Article › Research › peer-review

62 Citations (Scopus)

Abstract

Background. Intravesical instillations with bacillus Calmette-Gué rin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. Methods. There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. Results. Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. Conclusions. Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.

Original language	English
Pages (from-to)	1514-1516
Journal	Transplantation
Volume	76
Issue number	10
DOIs	https://doi.org/10.1097/01.TP.0000090748.32764.0F
Publication status	Published - 27 Nov 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/01.TP.0000090748.32764.0F

Cite this

@article{24d5dde7308349d0b391dbe5bb3bd28e,

title = "Intravesical bacillus Calmette-Gu{\`e}rin for the treatment of superficial bladder cancer in renal transplant patients",

abstract = "Background. Intravesical instillations with bacillus Calmette-Gu{\'e} rin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. Methods. There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. Results. Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. Conclusions. Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.",

author = "Juan Palou and Oriol Angerri and Jos{\'e} Segarra and Juan Caparr{\'o}s and Luis Guirado and Diaz, {Juan Manuel} and Jos{\'e} Salvador-Bayarri and Humberto Villavicencio-Mavrich",

year = "2003",

month = nov,

day = "27",

doi = "10.1097/01.TP.0000090748.32764.0F",

language = "English",

volume = "76",

pages = "1514--1516",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. / Palou, Juan; Angerri, Oriol; Segarra, José; Caparrós, Juan; Guirado, Luis; Diaz, Juan Manuel; Salvador-Bayarri, José; Villavicencio-Mavrich, Humberto.

In: Transplantation, Vol. 76, No. 10, 27.11.2003, p. 1514-1516.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients

AU - Palou, Juan

AU - Angerri, Oriol

AU - Segarra, José

AU - Caparrós, Juan

AU - Guirado, Luis

AU - Diaz, Juan Manuel

AU - Salvador-Bayarri, José

AU - Villavicencio-Mavrich, Humberto

PY - 2003/11/27

Y1 - 2003/11/27

N2 - Background. Intravesical instillations with bacillus Calmette-Gué rin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. Methods. There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. Results. Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. Conclusions. Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.

AB - Background. Intravesical instillations with bacillus Calmette-Gué rin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. Methods. There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. Results. Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. Conclusions. Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.

U2 - 10.1097/01.TP.0000090748.32764.0F

DO - 10.1097/01.TP.0000090748.32764.0F

M3 - Article

VL - 76

SP - 1514

EP - 1516

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -

Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this